


CLAIMS


1. A 1H-indazole-3-carboxamide compound having the following general formula (I):



wherein

- 5 R_a is a carbocyclic or heterocyclic ring, aliphatic or aromatic, having from 3 to 12 members, optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, C_1 - C_6 alkyl, hydroxy C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy C_1 - C_6 alkoxy, C_1 - C_6 alkoxy C_1 - C_6 alkyl, C_1 - C_6 alkoxy C_1 - C_6 alkoxy and C_1 - C_6 alkyl amino;
- 10 Y is a bond, a C_1 - C_6 alkyl, C_2 - C_6 alkenyl or C_2 - C_6 alkynyl group, optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, $-NH_2$, C_1 - C_3 alkyl and C_1 - C_3 alkoxy;
- 15 R_b is an aliphatic heterocyclic ring having from 5 to 10 members comprising at least one heteroatom selected from S and O, optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, $-NH_2$, oxo ($=O$), C_1 - C_3 alkyl and C_1 - C_3 alkoxy;
- and its salts of addition with pharmaceutically acceptable organic and inorganic acids and bases,
- 20 provided that when R_b is a oxanyl group, Y is not a bond, and when R_b is a oxolanyl group and R_a is a pyridinyl or a monofluoropyridinyl group, Y is not a $-CH_2-$ group.
2. The 1H-indazole-3-carboxamide compound according to claim 1, wherein R_a is a carbocyclic or heterocyclic ring, aliphatic or aromatic, having from 4 to 10 members.
3. The 1H-indazole-3-carboxamide compound according to claim 1, wherein R_a is a carbocyclic or heterocyclic ring, aliphatic or aromatic, having from 5 to 6 members.

4. The 1H-indazole-3-carboxamide compound according to claim 1, wherein R_a is an aromatic carbocyclic or heterocyclic ring, having 6 members, preferably a phenyl group or pyridinyl group.
5. The 1H-indazole-3-carboxamide compound according to claim 1, wherein Y is a bond or a C₁-C₆ alkyl group.
6. The 1H-indazole-3-carboxamide compound according to claim 1, wherein R_b is an aliphatic heterocyclic ring having from 5 to 6 members comprising at least one heteroatom selected from S and O.
7. The 1H-indazole-3-carboxamide compound according to claim 1, wherein R_b is an aliphatic heterocyclic ring having from 5 to 6 members comprising at least one oxygen atom.
8. The 1H-indazole-3-carboxamide compound according to claim 1, wherein R_b is a thiolanyl group, a oxolanyl group, a thianyl group or a oxanyl group.
9. The 1H-indazole-3-carboxamide compound according to claim 1, wherein R_b is a 1,1-dioxothiolanyl group, a oxolanyl group or a oxanyl group.
10. The 1H-indazole-3-carboxamide compound according to claim 1, wherein said C₁-C₆ alkyl amino is a C₁-C₆ alkyl group wherein one or more hydrogen atom of the alkyl chain is substituted by an amino group having the formula -NR₁R₂, wherein R₁ and R₂ are independently a hydrogen atom, a C₁-C₄ alkyl group, a C₂-C₄ alkenyl group, a C₂-C₄ alkynyl group, and a phenyl group, or R₁ and R₂ together with the nitrogen atom form an aliphatic heterocyclic ring having 5 to 6 members, optionally comprising at least one additional heteroatom selected from N, S and O.
11. The 1H-indazole-3-carboxamide compound according to claim 10, wherein said aliphatic heterocyclic ring formed by R₁ and R₂ together with the nitrogen atom of said -NR₁R₂ amino group is a pyrrolidine, oxazolidine, thiazolidine, piperidine, piperazine, morpholine, or thiomorpholine ring.
12. Use of 1H-indazole-3-carboxamide compounds having the following general formula (I):



wherein

5 R_a is a carbocyclic or heterocyclic ring, aliphatic or aromatic, having from 3 to 12 members, optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, C_1 - C_6 alkyl, hydroxy C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy C_1 - C_6 alkoxy, C_1 - C_6 alkoxy C_1 - C_6 alkyl, C_1 - C_6 alkoxy C_1 - C_6 alkoxy and C_1 - C_6 alkyl amino;

10 Y is a bond, a C_1 - C_6 alkyl, C_2 - C_6 alkenyl or C_2 - C_6 alkynyl group, optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, $-NH_2$, C_1 - C_3 alkyl and C_1 - C_3 alkoxy;


R_b is an aliphatic heterocyclic ring having from 5 to 10 members comprising at least one heteroatom selected from S and O, optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, $-NH_2$, oxo ($=O$), C_1 - C_3 alkyl and C_1 - C_3 alkoxy;

15 and its salts of addition with pharmaceutically acceptable organic and inorganic acids and bases;

20 for the treatment of a disease arising from the uncontrolled activation and/or overexpression of GSK-3 β , selected from the group consisting of (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) osteoporosis, (viii) cardiac hypertrophy, (ix) epilepsies and (x) neuropathic pain.

13. The use of a 1H-indazole-3-carboxamide according to claim 12, wherein said insulin-resistance disorders are selected from the group consisting of type-2 diabetes, syndrome X, obesity and polycystic ovary syndrome.

14. The use of a 1H-indazole-3-carboxamide according to claim 12, wherein said neurodegenerative diseases are selected from the group consisting of Parkinson's disease, Alzheimer's disease and Huntington's disease.
15. The use of a 1H-indazole-3-carboxamide according to claim 12, wherein said mood disorders are selected from the group consisting of bipolar disorders, such as bipolar I, bipolar II, cyclothymia and bipolar disorder not otherwise specified (BD-NOS), and depressive disorders, such as atypical depression (AD), melancholic depression, psychotic major depression (PMD), catatonic depression, postpartum depression (PPD), seasonal affective disorder (SAD), dysthymia, and depressive disorder not otherwise specified (DD-NOS).
16. The use of a 1H-indazole-3-carboxamide according to claim 12, wherein said schizophrenic disorders are selected from the group consisting of paranoid schizophrenia, disorganized schizophrenia, catatonic schizophrenia, simple schizophrenia, residual schizophrenia, and undifferentiated schizophrenia.
17. The use of a 1H-indazole-3-carboxamide according to claim 12, wherein said cancerous disorders are selected from the group consisting of prostate, pancreatic, ovarian, and colon-rectal cancer and MLL-associated leukaemia.
18. A method of treatment of a pathological state arising from the uncontrolled activation and/or over-expression of GSK-3 β , selected from the group consisting of (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) osteoporosis, (viii) cardiac hypertrophy, (ix) epilepsies and (x) neuropathic pain by the administration to a human being in need thereof of an effective amount of a 1H-indazole-3-carboxamide having the following general formula (I):



wherein

5 R_a is a carbocyclic or heterocyclic ring, aliphatic or aromatic, having from 3 to 12 members, optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, C_1 - C_6 alkyl, hydroxy C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy C_1 - C_6 alkoxy, C_1 - C_6 alkoxy C_1 - C_6 alkyl, C_1 - C_6 alkoxy C_1 - C_6 alkoxy and C_1 - C_6 alkyl amino;

Y is a bond, a C_1 - C_6 alkyl, C_2 - C_6 alkenyl or C_2 - C_6 alkynyl group, optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, $-NH_2$, C_1 - C_3 alkyl and C_1 - C_3 alkoxy;

10 R_b is an aliphatic heterocyclic ring having from 5 to 10 members comprising at least one heteroatom selected from S and O, optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, $-NH_2$, oxo ($=O$), C_1 - C_3 alkyl and C_1 - C_3 alkoxy;

and its salts of addition with pharmaceutically acceptable organic and inorganic acids and bases.

15 19. A pharmaceutical composition comprising an effective amount of at least one compound of formula (I) as defined in anyone of claims 1-11 above, a salt thereof with a pharmaceutically acceptable organic or inorganic acid or base, or a prodrug thereof, and at least one inert pharmaceutically acceptable excipient.